ArriVent Biopharma: Truist Securities recommends buying with a price target of $43!

ArriVent Biopharma (AVBP) positions itself as a clinical pharmaceutical company committed to the global development of innovative therapeutics for the treatment of hard-to-treat cancers. At the heart of the corporate strategy is the drug Firmonertinib, an orally administered third-generation tyrosine kinase inhibitor (TKI). This medication offers a potential solution for patients with non-small cell lung cancer (NSCLC) caused by specific mutations of the Epidermal Growth Factor Receptor (EGFR), particularly the rare but hard-to-treat EGFR Exon...